3.3.2.11: cholesterol-5,6-oxide hydrolase
This is an abbreviated version!
For detailed information about cholesterol-5,6-oxide hydrolase, go to the full flat file.
Word Map on EC 3.3.2.11
-
3.3.2.11
-
anti-estrogenic
-
oxysterols
-
diphenylmethane
-
hetero-oligomeric
-
hormonotherapy
-
medicine
-
drug development
- 3.3.2.11
-
anti-estrogenic
- oxysterols
- diphenylmethane
-
hetero-oligomeric
-
hormonotherapy
- medicine
- drug development
Reaction
Synonyms
anti-estrogen binding site, CEHase, ChEH, cholEH, cholesterol 5alpha,6alpha-oxide hydrolase, cholesterol epoxide hydrolase, cholesterol oxide hydrolase, cholesterol-5,6-epoxide hydrolase, cholesterol-epoxide hydrolase, EH_CH
ECTree
Advanced search results
Application
Application on EC 3.3.2.11 - cholesterol-5,6-oxide hydrolase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
-
the enzyme is a target for inhibition of the 6-oxo-cholestan-3beta,5alpha-diol (OCDO) biosynthesis in cancer therapy
medicine
-
in breast cancer tissue, cholesterol epoxide hydrolase ChEH metabolizes cholesterol-5,6-epoxide into cholestane-3beta,5alpha,6beta-triol, which is transformed into the oncometabolite 6-oxo-cholestan-3beta,5alpha-diol by 11beta-hydroxysteroid-dehydrogenase 11betaHSD2. ChEH inhibition and 11betaHSD2 silencing inhibit 6-oxo-cholestan-3beta,5alpha-diol production and tumor growth. Patient breast cancer samples show significantly increased 6-oxocholestan-3beta,5alpha-diol levels and greater ChEH and 11betaHSD2 protein expression compared with normal tissues, and 11betaHSD2 and ChEH overexpression correlate with a higher risk of patient death